Robert Dee Etherington - 26 Jun 2023 Form 4 Insider Report for Clene Inc. (CLNN)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CLNN
Reported as of: 26 Jun 2023
Net transaction value: +$20,250
SEC form: 4
Accepted by SEC: 27 Jun 2023, 08:07:48 UTC
Prior SEC filing: 07 Nov 2022
Next SEC filing: 03 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Jerry Miraglia POA

Key filing fact

Robert Dee Etherington filed Form 4 for Clene Inc. (CLNN) on 27 Jun 2023.

Key facts

This page summarizes Robert Dee Etherington's Form 4 filing for Clene Inc. (CLNN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Jun 2023, 08:07.

Change

Previous filing in this sequence was filed on 07 Nov 2022.
Current net transaction value: +$20,250.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLNN transaction

Common Stock

Purchase

Transaction value: $20,250
Shares: +25,000
Change %
Price: $0.8100
Shares after: 25,000
Date: 26 Jun 2023
Ownership: By Trust
Footnotes: F1, F2

CLNN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 56,593
Date: 26 Jun 2023
Ownership: Direct

CLNN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 12,717
Date: 26 Jun 2023
Ownership: By LLC
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Etherington Revocable Trust purchased 25,000 shares of common stock of Clene Inc. in multiple transactions on June 26, 2023 at prices ranging from $0.80 to $0.82, inclusive, for a weighted average price of $0.81 per share.

Footnote F2

The securities are owned by the Etherington Revocable Trust. Mr. Etherington is the co-trustee of the Etherington Revocable Trust. The shares owned by the Etherington Revocable Trust may be deemed to be beneficially owned by Mr. Etherington.

Footnote F3

The securities are owned by RDE RX Ventures LLC. Mr. Etherington is the manager of RDE RX Ventures LLC. The shares owned by RDE RX Ventures LLC may also be deemed to be beneficially owned by Mr. Etherington.